An ad hoc group formed by NCI to provide advice on the slowly-accruing TMIST—Tomosynthesis Mammographic Imaging Screening Trial—recommended that the trial be streamlined, but should continue.
A group of melanoma experts, joined by three advocacy groups focused on melanoma, has engaged FDA in a public discussion of the challenges of developing new drugs in the refractory setting and the role crossover can play in such trials.
